ADMA IVIG PREVENTS RSV INFECTION IN THE LUNGS OF IMMUNE COMPETENT COTTON RATS

**VIRAL TITER (log10 PFU/g)**

<table>
<thead>
<tr>
<th>GROUPS</th>
<th>0/5</th>
<th>2/5</th>
<th>2/5</th>
<th>0/5</th>
<th>2/5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ADMA IVIG PREVENTS RSV INFECTION IN THE NOSE OF IMMUNE COMPETENT COTTON RATS**

**REDUCTION OF VIRAL LOAD IN THE LUNG TISSUE OF COTTON RATS TREATED WITH RI-002 (log10 PFU)**

<table>
<thead>
<tr>
<th>GROUPS</th>
<th>0/5</th>
<th>2/5</th>
<th>2/5</th>
<th>0/5</th>
<th>2/5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ADMA IVIG PREVENTS RSV INFECTION IN THE LUNG OF IMMUNE COMPETENT COTTON RATS**

**PHASE II MULTICENTER DOSE RANGING STUDY IN RSV INFECTED IMMUNOCOMPROMISED PATIENTS**

<table>
<thead>
<tr>
<th>GROUPS</th>
<th>0/5</th>
<th>2/5</th>
<th>2/5</th>
<th>0/5</th>
<th>2/5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PHASE II PRIMARY OUTCOME**

**TREATMENT WITH RI-002 (log10 PFU)**

<table>
<thead>
<tr>
<th>GROUPS</th>
<th>0/5</th>
<th>2/5</th>
<th>2/5</th>
<th>0/5</th>
<th>2/5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SUMMARY FROM COMPASSIONATE USE TRIAL**

**VIRUS**

- Adenovirus
- Coronavirus
- Feline coronavirus
- Influenza
- Parainfluenza

**TREATMENT**

- Ribavirin
- Corticosteroids
- Glucocorticoids
- Immune globulin
- IVIG

**ADMA IVIG**

- Contains high neutralizing titer to RSV
- Prevents RSV pneumonia in normal and immune suppressed cotton rats
- Contains high neutralizing titers to RSV
- Failed conventional therapy
- CXR RUL consolidation

**VIGNETTES FROM COMPASSIONATE USE TRIAL**

**PATIENT #1**

- 2 year old female post BM transplant
- RSV+ (LRI)
- Patient clinically and symptomatically improved 2 days later.

**PATIENT #2**

- 45 year old male with CLL
- 2 weeks PTA increasing SOB
- Patient clinically and symptomatically improved 2 days later.

**SUMMARY**

- ADMA IVIG reduces and prevents RSV infection in normal and immuno compromised animals.
- ADMA IVIG contains high levels of RSV neutralizing antibodies that are biologically active.
- ADMA IVIG contains high levels of RSV neutralizing antibodies that are biologically active.
- ADMA IVIG is well tolerated in a phase IIA proof of concept study with normal and immune compromised animals.